NYSE$PRGO

Perrigo Company · Q3 2025 earnings

Q3 2025 earnings · · Before market open · Investor relations

Briefing

Perrigo reported Q3 results with modest EPS improvement, despite lower sales and margin compression.

Perrigo delivered Q3 2025 results reflecting continued headwinds from soft OTC market consumption and strategic portfolio reviews. Revenue fell 4.1% YoY, while adjusted EPS came in at $0.80, down slightly from $0.81. Adjusted operating margin held relatively stable at 16.6%.

  • Q3 revenue was $1.043 billion, down 4.1% YoY due to strategic reviews and OTC weakness.
  • GAAP EPS was $0.09 vs. a loss of ($0.13) YoY; adjusted EPS was $0.80 vs. $0.81.
  • Adjusted operating income declined 4.9% YoY to $173 million, with a 16.6% margin.
  • Cash and cash equivalents stood at $432 million; free cash flow was positive YTD at $63 million.

Headline financials

Total Revenue

$1.04B

Previous: $1.09B-4.1%
EPS (adj)

$0.80

Previous: -$0.15+633.3%
Capital Expenditures

-$66.6M

Previous: -$80.6M+17.4%
Free Cash Flow

$63.1M

Previous: -$102M+162.1%
Net Income

$12.7M

Previous: -$21M+160.5%
Operating Income

$72.6M

Previous: $80.4M-9.7%
Gross Profit

$377M

Previous: $404M-6.8%

Revenue & EPS history

Perrigo · Revenue · Quarterly

$1.04B

Q3 2025-4.1%vs Q3 2024
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Revenue by segment

Perrigo · $1.12B total across 2 segments · Q3 2023

  • Consumer Self-Care Americas
    $704M-2.5%
  • Consumer Self-Care International
    $420M+11.2%

Forward guidance

Perrigo revised its FY2025 guidance downward due to challenges in the infant formula business and soft OTC demand.

Tailwinds

  • FY25 adjusted EPS guidance maintained at $2.70–$2.80
  • Adjusted gross margin expected at ~39%
  • Adjusted operating margin guided at ~15%
  • Net leverage projected to improve to ~3.8x adjusted EBITDA
  • Ongoing savings from Project Energize expected to support margins

Headwinds

  • FY25 revenue projected to decline 2.5% to 3.0%
  • Organic net sales expected to fall 2.0% to 2.5%
  • Infant formula industry dynamics remain a headwind
  • OTC consumption softness expected to persist
  • Ongoing strategic reviews (Infant Formula, Oral Care) reflect portfolio instability

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

-1.5%

Avg return

Earnings day

-2.1%

Avg return

5 days after

-3.4%

Avg return

30 days after

48%

30 / 63 earnings

Positive

+20.2%

Q4 2024

Best reaction

-25.2%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+5.3%-5.0%-7.0%
Q4 2025-1.5%-21.0%-33.9%
Q3 2025-25.2%-29.4%-33.4%
Q1 2025+7.2%+9.4%+6.0%
Q4 2024+20.2%+22.1%+16.3%
Q3 2024+6.2%+5.4%+10.7%
Q2 2024+1.8%-1.5%+3.3%
Q1 2024-6.9%-8.1%-19.2%
Q4 2023-17.9%-18.2%+0.1%
Q3 2023+2.0%-0.2%+7.3%
Q2 2023+5.8%+7.3%-8.4%
Q1 2023+1.3%-2.2%-6.5%
Q4 2022+3.9%+6.9%-3.2%
Q3 2022-18.3%-14.9%-18.2%
Q2 2022-1.9%-1.7%-9.3%
Q1 2022+9.1%+15.6%+19.7%
Q4 2021+6.4%+4.8%+8.2%
Q3 2021-8.7%-9.8%-23.0%
Q2 2021-16.0%-16.6%-11.1%
Q1 2021+6.1%+6.4%+13.3%
Q4 2020+4.3%+1.7%+0.3%
Q3 2020-0.3%+1.5%+9.9%
Q2 2020-8.5%-6.1%-7.7%
Q1 2020-3.0%-4.4%+0.8%
Q4 2019-16.4%-12.1%-24.0%
Q3 2019-8.1%-9.3%-3.4%
Q2 2019-7.1%-5.4%-1.1%
Q1 2019+7.5%+1.7%-10.1%
Q4 2018+0.8%+4.0%-0.3%
Q3 2018-14.7%-13.0%-20.2%
Q2 2018-10.7%-11.3%-3.3%
Q1 2018-4.9%+0.4%-5.2%
Q4 2017+1.9%-6.0%-5.6%
Q3 2017+8.0%+5.9%+5.4%
Q2 2017+18.3%+17.2%+24.7%
Q1 2017+4.1%+5.0%+8.5%
Q3 2016+6.9%+6.7%-1.2%
Q2 2016-9.8%-7.2%-6.7%
Q1 2016-4.7%
Q4 2015-10.9%
Q3 2015-1.3%
Q2 2015+1.7%
Q1 2015-1.7%
Q4 2014+6.7%
Q3 2014-11.3%
Q2 2014-4.9%
Q1 2014+10.7%
Q4 2013-5.1%
Q3 2013-0.5%
Q2 2013+5.2%
Q1 2013-8.8%
Q4 2012-8.3%
Q3 2012-4.5%
Q1 2012+1.8%
Q2 2012-0.1%
Q4 2011+1.3%
Q3 2011-7.6%
Q2 2011+2.7%
Q1 2011+1.7%
Q4 2010+0.6%
Q3 2010-0.1%
Q2 2010-2.9%
Q1 2010+0.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro